We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Customized Monoclonal Antibody Design Highlighted at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 31 Jul 2013
Print article
Image: Customized monoclonal antibodies by MedixMAB by Design (Photo courtesy of Medix Biochemica).
Image: Customized monoclonal antibodies by MedixMAB by Design (Photo courtesy of Medix Biochemica).
Biotech researchers and other life scientists working with monoclonal antibodies (MABs) who are attending the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013, are invited to learn how to exploit the services of an innovative developer and producer of custom-made recombinant antibodies.

Medix Biochemica (Kauniainen, Finland), producer of monoclonal antibodies for the global IVD industry and of proprietary rapid diagnostic tests, is highlighting its MedixMAB by Design antibody production service at the Clinical Lab Expo.

By offering a completely customized service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design paves the way for the development of superior IVD assays. Antibodies are produced to the strictest international quality standards, and this new service gives IVD manufacturers access to topflight biological without the need to invest in costly production facilities and expertise.

Medix makes monoclonal antibodies using an advanced in vitro system, which incorporates the latest in cutting-edge phage display-production technology. These antibodies can target a broad range of antigens, including poorly immunoreactive and toxic compounds. Successful recombinant antibodies can then easily be produced in bulk quantities. Alternatively, Fab fragments, which greatly enhance specificity and sensitivity of solid-phase IVD assays, can be generated in just three months. All development and manufacturing processes are comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and [US] FDA QSR quality standards.

Maija Partanen, product manager for MedixMAB by Design, said, “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”

Related Links:

Medix Biochemica



Gold Supplier
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Laboratory Automation System
UniVerse
New
Laboratory Water System
Q-CHE40-SR/Q-CHE80-SR
New
Respiratory Multiplex RT-PCR Kit
Respiratory Multiplex RT-PCR Kit

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.